The gene therapy market is characterized by a healthy drug pipeline, with 10 approved molecules and over 820 product candidates {Roots Analysis}

 

Success of approved gene therapies has resulted in a surge in interest of biopharmaceutical developers in this rapidly evolving domain. Presently, the ability of gene therapies to treat diverse disease indications is considered among the most prominent drivers of this market. In addition, promising clinical results of pipeline candidates are anticipated to draw in more investments to support product development initiatives.

 

To order this 720+ page report, which features 220+ figures and 375+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html

 

The USD 14.6 billion (by 2030) financial opportunity within the gene therapy market has been analyzed across the following segments:

§  Therapeutic approach

§  Gene augmentation

§  Oncolytic therapy

§  Immunotherapy

§  Others

 

§  Type of gene therapy

§  Ex vivo

§  In vivo

 

§  Type of vector used

§  Adeno associated virus

§  Adenovirus

§  Herpes simplex virus

§  Lentivirus

§  Plasmid DNA

§  Retrovirus

§  Others

 

§  Key therapeutic areas

§  Autoimmune disorders

§  Cardiovascular diseases

§  Dermatological disorders

§  Genetic disorders

§  Hematological disorders

§  Metabolic disorders

§  Muscle-related diseases

§  Oncological disorders

§  Ophthalmic diseases

§  Others

 

§  Route of administration

§  Intraarticular

§  Intracerebellar

§  Intradermal

§  Intramuscular

§  Intratumoral

§  Intravenous

§  Intravesical

§  Intravitreal

§  Subretinal

§  Others

 

§  Key geographical regions

§  North America

§  Europe

  • Asia-Pacific 

 

The Gene Therapy Market (4th Edition), 2020-2030 report features the following companies, which we identified to be key players in this domain:

§  Abeona Therapeutics

§  Advantagene

§  Biogen

§  bluebird bio

§  Castle Creek Biosciences

§  CG Oncology

§  FerGene

§  Freeline Therapeutics

§  Gradalis

§  Helixmith

§  Inovio Pharmaceuticals

§  Kolon TissueGene

§  Krystal Biotech

§  Lysogene

§  Neurophth Therapeutics

§  OncoSec Immunotherapies

§  Orchard Therapeutics

§  Pfizer

§  Sangamo Therapeutics

§  Spark Therapeutics

§  uniQure Biopharma

§  VBL Therapeutics

 

Table of Contents

 

1. Preface

2. Executive Summary


3. Introduction

4. Gene Delivery Vectors

5. Regulatory Landscape and Reimbursement Scenario

6. Market Overview

7. Competitive Landscape 

8. Marketed Gene Therapies

9. Key Commercialization Strategies

10. Late Stage (Phase II/III and Above) Gene Therapies

11. Emerging Technologies

12. Key Therapeutics Areas

13. Patent Analysis

14. Mergers and Acquisitions

 

15. Funding and Investment Analysis

 

16. Clinical Trial Analysis

 

17. Cost Price Analysis

 

18. Big Pharma Players: Analysis of Gene Therapy Related Initiatives

 

19. Demand Analysis

 

20. Market Forecast and Opportunity Analysis

 

21. Vector Manufacturing

 

22. Case Study: Gene Therapy Supply Chain

 

23. Conclusion

 

24. Interview Transcripts

 

25. Appendix 1: Tabulated Data

 

26. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com 

Comments

Post a Comment

Popular posts from this blog

A relatively larger proportion of these firms are headquartered in the US, claims Roots Analysis

  Lately, drug manufacturers have started showing evident interest in modular facilities and using modularity in design approaches owing to the amplified value of smaller production facilities, which are more efficient and flexible. The increased demand for multi-product, multi-purpose, smaller batch size facilities has also prompted equipment manufacturers to revisit their product offerings.   To order this 300+ page report, which features 120+ figures and 130+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/modular-facilities-flexible-drug-manufacturing-platforms-of-the-future/178.html   The USD xx billion (by 2030) financial opportunity within the modular facilities market has been analyzed across the following segments: ·        Type of Modular Construct  §   Hybrid Skid §   Plug-and-Play §   Skid-Mounted §   Truckable §   Others §   Type of Construc...
Read more

The subcutaneous biologic drugs and affiliated technologies market is projected to be worth over USD 180 billion by 2030

    Subcutaneous drug delivery, given the use of tailored formulation development solutions, has brought about a paradigm shift in at-home healthcare, enabling users to administer (life-saving) medications without having to rely on medical professionals   Roots Analysis is pleased to announce the publication of its recent study, titled “ Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030 ” report to its list of offerings.   The report provides a detailed study on the current market landscape and future potential of biologics designed for subcutaneous administration. In addition, the study provides an in-depth analysis of the formulation technologies and drug delivery systems (focusing on large volume wearable injectors, autoinjectors, pen injectors, needle-free injectors, drug reconstitution systems, prefilled syringes and implants) that enable subcutaneous delivery of the biologic drugs. Amongst other elements, the r...
Read more

PRE-INSTALLED SINGLE-USE SENSORS FOR BIOPROCESSING-CASE STUDY

    During our research, we identified 31 pre-installed single-use sensors developed by various companies for bioprocessing. The current market landscape is predominantly characterized by the presence of large (38%) and small (37%) players. Notable examples of large players in this domain include ( in alphabetical order ) Cytiva Life Sciences (US), Hamilton (US) and Pall (US).   To Request Sample Pages -: https://www.rootsanalysis.com/reports/single-use-sensors-for-bioprocessing.html       Majority of the pre-installed single-use sensor systems are designed for both, research and biomanufacturing purposes. This is followed by those designed for only research purposes. Notable examples of products which are developed for both research and biomanufacturing applications, include ( arranged alphabetically ) ÄKTA ready XL sensor technology (Cytiva Life Sciences), Allegro™ MVP Single-Use System (Pall Corporation) and FUTURA pico (Aber Instruments)...
Read more